


 Cite this: *RSC Adv.*, 2022, **12**, 15385

 Received 10th March 2022
 Accepted 27th April 2022

DOI: 10.1039/d2ra01571d

rsc.li/rsc-advances

Pyridine: the scaffolds with significant clinical diversity

 Sourav De,^a Ashok Kumar S K,^b Suraj Kumar Shah,^a Sabnaz Kazi,^a Nandan Sarkar,^a Subhasis Banerjee^c and Sanjay Dey^a

The nitrogen-bearing heterocycle pyridine in its several analogous forms occupies an important position as a precious source of clinically useful agents in the field of medicinal chemistry research. This privileged scaffold has been consistently incorporated in a diverse range of drug candidates approved by the FDA (Food and Drug Administration). This moiety has attracted increasing attention from several disease states owing to its ease of parallelization and testing potential pertaining to the chemical space. In the next few years, a larger share of novel pyridine-based drug candidates is expected. This review unifies the current advances in novel pyridine-based molecular frameworks and their unique clinical relevance as reported over the last two decades. It highlights an inclination to the use of pyridine-based molecules in drug crafting and the subsequent emergence of several potent and eligible candidates against a range of diversified diseases.

1. Introduction

Pyridine (C₅H₅N), an isostere of benzene, is used as a precursor for synthesizing target pharmaceuticals and agrochemicals. Besides, it is a key solvent and reagent. The term 'pyridine' is a derivative from a Greek word, and is the grouping of two words "pyr" denotes fire and "idine" is applicable for aromatic bases. The initial pyridine scaffold was isolated from picoline by Anderson in 1846. Later, Wilhelm Korner (1869) and James Dewar (1871) discovered the structure of pyridine. William Ramsay had prepared a pyridine-based compound by mixing acetylene and hydrogen cyanide under red-hot conditions. In the formulation of pharmaceuticals, pyridine is one of the nuclear components of more than 7000 existing drug molecules of medicinal importance. Pyridine scaffolds are found in nature, mainly from plant resources, such as alkaloids and one of the most effective cholinergic drugs like atropine (*Atropa belladonna*), which holds a saturated pyridine ring.^{1,2} In many enzymatic reactions, prosthetic pyridine nucleotide is engaged in numerous oxidation–reduction processes. Many vitamins, such as pyridoxine, niacin and nicotine, have high potency and selectivity in many biological systems.

Topical isolation of the structurally-modified natural products diploclonide and nakinadine contain pyridine moiety. Atazanavir (Rey-ataz) and imatinib mesylate (Gleevec) are

medicinally-active pyridine derivatives. These drugs are useful against human immune deficiency virus (HIV) and chronic myelogenous leukemia. The chief constituent of coenzyme nicotinamide adenine dinucleotide (NADH) and nicotinamide adenine dinucleotide phosphate (NADPH) are prepared either from the 1-tryptophan kynurenine pathway in animals or the glyceraldehyde-3-phosphate and aspartic acid pathway in different plants. Anabasine, ricinine and arecoline are derived from nicotinic acid (Fig. 1), while in industrial scale-up processes they are prepared by using a mixture of crotonaldehyde, formaldehyde and ammonia in a gas phase.

Ammonia has been used as the nitrogen source in countless protocols, such as [5 + 1] condensation with 1, 5 dicarbonyls (Scheme 1). Autoxidation is an important factor for aromatization in different condensation processes. In the [2 + 2 + 1 + 1] Hantzsch pyridine synthesis, ammonia is regularly used (Scheme 2). Further, the preparation of pyridine depends on alkyl or vinyl amine and is a type of condensation reaction between 1, 3 dicarbonyl derivatives and vinylogous amide (Scheme 3).

Boger *et al.* have synthesized [4 + 2] pyridine by introducing enamines and triazine *via* an inverse electron demand azadiels–Alder reaction (Scheme 4). The key approaches are 6π-electrocyclization (Scheme 5) using a [2 + 2 + 2] cobalt-mediated synthesis of substituted pyridines (Scheme 6).³

2. Pharmacology

2.1 Antibacterial activity

Ivachtchenko *et al.* synthesized 2-imino-5-hydroxymethyl-8-methyl-2*H*-pyrano[2,3-*c*] pyridine-3-(*N*-aryl) carboxamides (**1**) that exhibited potency and selectivity (12.5–25 lg mL⁻¹) toward

^aDepartment of Pharmaceutical Technology, School of Medical Science, Adamas University, Kolkata-700126, West Bengal, India. E-mail: sourav1.de@adamasuniversity.ac.in

^bDepartment of Chemistry, School of Advanced Sciences, VIT, Vellore-632014, India. E-mail: ashokkumar.sk@vit.ac.in

^cDepartment of Pharmaceutical Chemistry, Gupta College of Technological Sciences, Asansol-713301, West Bengal, India







Fig. 1 Examples of naturally occurring pyridine derivatives.

fungal and bacterial straining and was also highly active in comparison with marketed drugs.⁴ Suksrichavalit *et al.* prepared the pyridine-based copper complexes (2–5) and evaluated them for superoxide scavenging and antimicrobial properties. These complexes showed superoxide dismutase activity in the range of 49.07–130.23 mM. One of copper complex based nicotinic acid with 2-hydroxypyridine showed inhibitory concentration of 49.07 mM.⁵ Bhatia *et al.*, reported a set of pyridine scaffolds (6a–6h) obtained by reacting pyridyl amine with the aromatic aldehyde. All the synthesized compounds were screened for their antibacterial and antitubercular activities in the range of 3.12–6.25 $\mu\text{g mL}^{-1}$.⁶ Leal *et al.* have evaluated the biological and theoretical studies of 4-(arylamino)-1-phenyl-1*H*-pyrazolo [3,4-*b*]pyridine-5-carboxylic acids (7), which indicated that compound 7 exhibited potent antibacterial efficacy against a drug-resistant *S. epidermidis*. The minimum inhibitory concentration of the prepared compound showed similar pharmacological activity in comparison with


oxacillin and better potency with chloramphenicol.⁷ The thienopyridine and other pyridines (8–16), as developed by Zavyalova, were found to be effective against both Gram-positive bacteria, *S. aureus* and Gram-positive bacteria as *E. coli*, *P. aeruginosa* and *P. vulgaris*⁸ (Fig. 2). Sharma *et al.* reported a substituted pyridine analog (17) and evaluated its pharmacological properties such as antibacterial activity.⁹

2.2 Antiviral activity

Bernardino *et al.* synthesized a series of 4-(phenylamino)thieno [2,3-*b*]pyridine derivatives (18) and evaluated their inhibitory property against Herpes simplex virus type 1 (HSV-1). All the synthesized derivatives were chemically diverse in nature but showed moderate potency. To enhance the efficiency, similar type of derivatives with a new series of 4-(phenylamino)-1*H*-pyridazino [3,4-*b*]pyridine derivatives (19) were prepared and




Scheme 1 Synthesis of substituted pyridines by a condensation method.



Scheme 2 [2 + 2 + 1 + 1] multicomponent synthesis of pyridine derivatives.





Scheme 3 A one-pot synthesis of substituted pyridines from 1,3-dicarbonyl and vinylogous amide.

these analogues exhibited better anti-HIV activity, as compared to those in the earlier series.¹⁰


Attia *et al.* reported the preparation of a few pyridine ribosides (**20**) and subsequently inferred their potentiality against HIV infection. 1-(β -D-ribofuranosyl)-pyridine-2-thione with the substituent (phenyl, 4-chlorophenyl, methylphenyl, 4-furyl) was found to be the most active one.¹¹ Chezal *et al.* have synthesized a series of imidazo pyridine scaffolds (**21**) and evaluated the antimicrobial efficacy towards classical swine fever virus and the border disease virus which belongs to the genus Pestivirus.¹² A few thiazolo pyridine-based oxime exhibit better potency towards influenza B-Mass virus. In continuation, the above compounds also showed better selectivity and activity against HIV. Many naphthyridine compounds have been evaluated for their antibacterial activity and oximes-pyridine scaffolds as antidotes against organophosphorus poisoning (**22**).¹³ Hydrazone of 3 and 4-acetyl pyridine, which has anti-tumor activity, is capable of inhibiting the replication of RNA (+) and RNA (-)

strains of hepatitis C-virus (HCV) (**23**). Bi-pyridinyl derivatives complex with ruthenium displayed antiviral property against HCV (**24**).¹⁴ Chen *et al.* synthesized chalcone scaffolds, which contained malonate and pyridine moieties (**25a–25v**). The compound **25i** and **25n** exhibited notable curative activities¹⁵ along with potent antiviral activity towards cucumber mosaic virus (CMV) at 500 $\mu\text{g mL}^{-1}$ with EC_{50} values of 186.2 and 211.5 $\mu\text{g mL}^{-1}$, respectively. The results are comparatively better than that of ningnanmycin (330.5 $\mu\text{g mL}^{-1}$) (Scheme 7).


Hartwich *et al.* synthesized phosphonylated triazolo[4,5-*b*]pyridine(1-deaza-8-azapurine) (**26a**), imidazo[4,5-*b*]pyridine (1-deazapurine) (**26b**) and imidazo[4,5-*b*]pyridin-2(3*H*)-one(1-deazapurin-8-one) (**26c**) were evaluated for antimicrobial properties. Compound **26c** exhibited minimal activity ($\text{EC}_{50} = 61.70 \mu\text{M}$) when exposed to the varicella-zoster virus Oka strain in HEL cells¹⁶ while the other two compounds exhibited marginal activity (Fig. 3).

2.3 Anticancer activity


Nicolaou *et al.* proposed pyridine epothilones and evaluated their cytotoxicity against a number of human cancer cell lines. Compounds (**27**) and (**28**) exhibited the highest activity, which may be ascribed to the ring nitrogen and the pyridyl methyl group at 5th and 6th positions, respectively.¹⁷ Here, it is worth mentioning that the presence of pyridine nitrogen has traditionally been assumed to be protonated in enzyme active sites, with the protonated pyridine ring providing resonance stabilization of carbanionic intermediates. Therefore, the ring



Scheme 4 Synthesis of pyridine derivatives via the aza-Diels–Alder method.



Scheme 5 The [4 + 2] rhodium-mediated synthesis of pyridines.



Scheme 6 [2 + 2 + 2] cobalt-mediated synthesis of substituted pyridines. Cbz = carbobenzyloxy, Cod = cyclooctadiene.







Fig. 2 Some examples of most anti-bacterial agent of substituted pyridines.

nitrogen in the pyridyl system plays a crucial role in controlling the enzyme activity and hence impacts the potent biological attributes of analogues.

A series of a few 2,6-diaryl-substituted pyridines (29) was synthesized by Jong-Keun Son *et al.* and reported their cytotoxic

effect against several human cancer cell lines. Compounds with their substituents revealed promising cytotoxic topoisomerase I inhibitory activity.¹⁸ Hayakawa *et al.* prepared a series of imidazo [1,2-*a*] pyridines scaffolds (30) and tested their p110a (emerging target for cancer therapy) inhibitory property. Only,





Scheme 7 Synthesis of most active antiviral agent chalcone conjugate with malonate and pyridine.

thiazolyl imidazo [1,2-*a*] pyridine compound showed inhibition of tumor cell growth.¹⁹

A series of 2-amino-3-(3',4',5'-trimethoxybenzoyl)-6-substituted-4,5,6,7-tetrahydrothieno [2,3-*c*] pyridine derivatives

(31) was evaluated for anticancer properties against several cancer cell lines, as reported by Romagnoli *et al.* These substituted compounds exhibited promising anti-proliferative activity. The mechanistic study suggested that the inhibition




Fig. 3 Representative examples of antiviral activity of compounds containing pyridine as the basic unit.







Fig. 4 Representative examples of the most active anticancer agents.


of tubulin polymerization may affect the G2 cell cycle.²⁰ Liou *et al.* established a new indoline-sulfonamide (**32**) derivative and evaluated its anticancer properties for various human cancer cell lines *via* disruption of microtubule.²¹ The cobalt(III)

pyridine complexes (**33**) and (**34**) as reported by Nagababu *et al.*²² efficiently interact with DNA. These complexes showed their photocleavage ability on plasmid DNA pBR322 upon irradiation at 365 nm (Fig. 4).



Scheme 8 Reagents and conditions for synthesizing of most active anticancer agent pyridine-ureas **35a–n**; (i) DMF-DMA, xylene, reflux 7 h; (ii) NH₄OAc, AcOH, reflux 4 h; (iii) methanol, NH₂NH₂·H₂O, reflux 2 h; (iv) NaNO₂, AcOH, stirring 2 h; (v) xylene, reflux 1 h; (vi) xylene, reflux 3 h.





Scheme 9 Synthesis of curcumin-inspired imidazo[1,2-*a*]pyridine analogues **36a–t**; reagents and conditions: (i) 15% NaOH, ethanol, 0 °C – rt, 2–3 h, 71–85%. (ii) Ethanol, reflux, 1 h, 74.3%; (iii) NIS, rt, 1 h, 65.1%; (iv) Pd(PPh₃)₄, Na₂CO₃, dioxane : H₂O = 8 : 2, 75 °C, 2–6 h, 65–73%; (v) LiAlH₄, THF, 0 °C – rt, 1 h, 67–71%; (vi) DMP, DCM, 0 °C, 1 h, 65–74%; (vii) CH₃ONa, ethanol, rt, 15 min, 63–82%.

El Naggar *et al.* synthesized pyridine-ureas (**35a–n**) and evaluated the *in vitro* anti-proliferative activity against MCF-7. The observed IC₅₀ values are micromolar region, which is beneficial for getting good pharmacological activity (Scheme 8).²³

Ramya *et al.* synthesized a series of curcumin-conjugated imidazo[1,2-*a*]pyridine (**36a–t**) as a tubulin polymerization inhibitor. Among these, compounds **36e**, **36r** and **36t** demonstrated potent growth inhibition and **36t** demonstrated low IC₅₀ values 1.7–2.97 μM with different cancer cell lines. Moreover,





Fig. 5 Most active anticancer agent curcumin conjugated imidazo[1,2-*a*]pyridine derivatives.





Scheme 10 Synthesis of most active anticancer agent dipyrindinyl-thiazole sugar and acrylidine derivatives.

36t showed a good cytotoxicity profile on PC-3, HGC-27 and HeLa cell lines with IC_{50} values of $2.11 \pm 0.27 \mu\text{M}$, $2.21 \pm 0.25 \mu\text{M}$ and $2.53 \pm 0.01 \mu\text{M}$, respectively (Scheme 9 and Fig. 5).²⁴


Khalaf *et al.* synthesized a number of dipyrindyl (37–39) or pyridinyl sugar hydrazones linked to thienyl or the methylfuryl rings in addition to pyridine thioglycosides combining naphthyl and furyl systems *via* a multistep process. The prepared compounds showed higher cytotoxicity profiles toward various cancer cell lines. Anticancer activity of the products was tested against human prostatic adenocarcinoma (PC3), adenocarcinomic human alveolar basal epithelial (A549) and human colorectal carcinoma (HCT116) cell lines in addition to their effect on human normal retinal pigmented epithelial cell line (RPE1) using the MTT assay (Schemes 10–12).²⁵

Thongaram *et al.* developed a tandem reaction between 3-hydroxy-2-methylpyridine 1-oxide and substituted 2-fluorobenzaldehydes (44), which involved Knoevenagel condensation and nucleophilic aromatic substitution (Fig. 6). This type of reaction provides easy contact with pyridine 1-oxide derivatives

with good yields. Among these, a few are highly potent and selective toward HCT-116 cell lines with IC_{50} values 24.95–45.80 μM .²⁶

Mansour *et al.* investigated the cytotoxicity against MCF-7 and MDA-MB-231 cell lines for some new chemical entities at different concentrations (0–100 $\mu\text{g mL}^{-1}$) *via* the MTT assay. Compounds (45–48) were found with the lowest half-maximal inhibitory concentrations (IC_{50}) against those cell lines by cytotoxicity assays.²⁷ Rani *et al.* have synthesized a new set of amide derivative imidazopyridine (49a–49j) compounds exhibiting anticancer activities when exposed to the breast (MCF-7 and MDA-MB-231) cancer, lung (A549) cancer, and prostate (DU-145) cancer cell lines *via* MTT assay (etoposide as the standard reference drug). Among those compounds, 49j showed the highest anticancer activities towards MDA-MB-231, MCF-7, A549 and DU-145 cell lines with the IC_{50} values of $0.95 \pm 0.039 \mu\text{M}$, $0.021 \pm 0.0012 \mu\text{M}$, $0.091 \pm 0.0053 \mu\text{M}$, and $0.24 \pm 0.032 \mu\text{M}$, respectively²⁸ (Scheme 13).





Scheme 11 Synthesis of most active anticancer agent heteroaryl-substituted pyridine glycosides.


Barresi *et al.* reported vinyl-substituted pyridine (50, 51) compounds showing the antitumor activities (*in vitro*) of the synthesized compounds.²⁹ The compounds 50a–50d and 51a, 51c, 51e showed *in vitro* antitumor antiproliferative activity, particularly evident in the MCF7 mammary adenocarcinoma cells. Son *et al.* synthesized and reported diaryl-based pyridine (52) compound having antitumor properties.³⁰ Cocco *et al.* reported the synthesis of antitumoral complex dicyanopyridine (53) and (*in vitro*).³¹ Ester and amide of 2-arylamino-6-trifluoromethyl-3-pyridinecarboxylic acids (54,55) possess antitumor properties, as reported by Onnis *et al.*³² (Fig. 7).

2.4 Antidiabetic activity

Type 1 diabetes mellitus (T1DM) can be produced with Streptozotocin (STZ) by the pancreatic islet β -cell destruction. Type 2 diabetes models are also going to be developed using STZ. Several animal species *e.g.* the mouse, rat, and monkey, are more sensitive to the pancreatic β -cell cytotoxic effects of STZ

compared to a rabbit. Animals such as rats and mice are being used for assessing the pathological consequences and potential therapies/treatments in diabetes patients.³³ Bahekar *et al.* reported two sets of pyrrolo-based pyridine derivatives and thieno-based pyridines, respectively (56–58). All the compounds exhibit *in vitro* glucose-dependent insulinotropic activity towards RIN5F cell lines.³⁴ Kim *et al.* reported the synthesis of a few thiazolidinedione-based pyridines compounds (59) and showed the hypoglycemic activity and hypolipidemic activity of the synthesized compounds.³⁵ Suresh *et al.* developed isoxazolo-based pyridine (60–64) heterocycles by an environmentally benign method. The synthesized compound (63) showed the highest inhibition of α -amylase activity ($IC_{50} = 56.043 \mu\text{g mL}^{-1}$).³⁶ Adi *et al.* reported a new set of antimicrobial complexes (Scheme 14) 65a–p, which showed *in vitro* yeast α -glucosidase inhibitory activity with IC_{50} values ranging from 101.0 ± 2.0 to $227.3 \pm 1.4 \mu\text{M}$, which was higher than that of the standard drug acarbose ($IC_{50} = 750.0 \pm 1.5 \mu\text{M}$) (Fig. 8 and 9).³⁷





Scheme 12 Synthesis of most active anticancer agent pyridinyl furan sugar derivatives.

Ma *et al.* synthesized a new class of complexes of thienopyridine derivatives, which act as hepatic gluconeogenesis inhibitors that were found to be effective in type 2 diabetes mellitus (Fig. 10). The structure–activity relationship (SARs) study proved that thienopyridine core can increase the antimicrobial potency when replaced with $-\text{CF}_3$, which led to the synthesis of a couple of complexes **66e** ($\text{IC}_{50} = 16.8 \mu\text{M}$) and **67d** ($\text{IC}_{50} = 12.3 \mu\text{M}$) that can inhibit the production of hepatic glucose. Added to this, complex **61e** also showed similar activity and a decrease in the expression of the mRNA transcription

level of gluconeogenic genes, including hepatic phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase).³⁸

2.5 Antifungal activity

Ozdemir *et al.* reported a group of eight novel pyridine derivatives showing antifungal activity when exposed to a panel of ten human pathogenic *Candida* species (Fig. 11). Among them, compound (**68**) exhibited strong inhibition ($\text{MIC } 0.016 \text{ mg mL}^{-1}$) against the screened *Candida* species.³⁹ The synthesis






Fig. 6 Synthesis of most active anticancer agent pyridine derivatives.


and antifungal activities of a few 3-aryl-5-(pyridin-3-yl)-4,5-dihydropyrazole-1-carbothioamide (**69**) were reported by Shekarchia *et al.*⁴⁰

Pyridine quaternization was performed using the betulin triterpenoids as the lipophilic substrates and Tempo + Br³ – cation. The application of Tempo + Br³ – cation provides *in situ* substrate bromination, which avoids the stage of additional halogenations. This process significantly reduces the number of stages, and it increases the final yield of the reaction product (Fig. 12). The obtained quaternized pyridine

derivatives of betulin triterpenes showed good antibacterial and antifungal activities compared to the initial compounds.^{41–44}

2.6 Anti-inflammatory and anti-mycobacterial studies

A few diversified amides upon condensing with 2/4-acetyl pyridine connected to imidazo[1,2-*a*]pyridines (**70**) were evaluated for their anti-inflammatory property. Both the acetylated compounds exhibited an excellent anti-inflammatory



Scheme 13 Synthesis of most active anticancer agent amide derivatives of imidazopyridine.








Fig. 8 Most active anticancer agent Imidazolopyridine and bipyridine derivatives.

Fig. 9 *In vitro* yeast α -glucosidase inhibition activity with IC₅₀ values.

Mishra *et al.* reported a novel carboxamido pyridyl-based thiazolidinediones complex (**81**) showing antimicrobial activity.⁵⁷ Mehta *et al.* reported that some of the thiazolidinone contains pyridine (**82**), which is a new class of antimicrobial agents.⁵⁸ Aanandhi *et al.* reported a group of pyridine based thiosemicarbazide complexes (**83**) exhibiting antimicrobial

Fig. 10 Most active anticancer agent thieno[2,3-*b*]pyridine derivatives.

activity.⁵⁹ The antimicrobial activity of compounds indicated that few derivatives showed the highest activity against *B. subtilis* NCIM2063, *S. aureus* NCIM2079, *E. coli* NCIM2065, *P. aeruginosa* NCIM2200, *C. albicans* NCIM3102 and *A. niger*. Riahi *et al.* prepared and demonstrated antimicrobial activity for the pyridyl-based carbonyl complex.⁶⁰ Vora *et al.* reported and examined the antimicrobial activity of Schiff base methyl pyridine amine (**85**).⁶¹

2.8 Anti-tubercular activity

Sriram *et al.* synthesized phenyl-based thiourea (**86**) and studied its *in vitro* antitubercular activity.⁶² Compound **86** showed the






Fig. 11 Most active antifungal agent pyridine derivatives.




Fig. 12 Quaternized pyridine derivatives of betulin triterpenes demonstrate antibacterial and antifungal activities.




Fig. 13 Structures of 2/4-acetyl pyridine connected to imidazo[1,2-a]pyridines.

highest antitubercular activity. Herzigova *et al.* studied 4-benzylsulfanylpyridine-2-carbohydrazides (**87**) and established their potential anti-tubercular property⁶³ (Fig. 15).

2.9 Antichagasic, anti-oxidant, anti-malarial, anti-amoebic agents, iron overload disease and enzyme inhibition

Endemic of Chagas' disease can keep a hundred million people at risk and about twenty million people are infected chronically. *Trypanosoma cruzi* parasite is responsible for this disease. To prevent this, Dias *et al.* synthesized antichagasic 1*H*-pyrazolo [3,4-*b*] pyridine series compounds (**88**) (Fig. 16).⁶⁴

The synthesis and free radical scavenging activity of thiazolo [3,2-*a*] pyridines (**89**) were reported by Feng Shi *et al.* (Fig. 17).⁶⁵

The substituted thiazolopyridines showed significant superoxide dismutase (SOD) property. Studies show that molecular compounds with the lowest atomic polarizability have the highest DPPH activity.⁶⁶ Timperley *et al.* have synthesized and evaluated the activity of mono- and bis-quaternary pyridine salts (**90**) in organophosphorus poisoning treatment (Fig. 18).⁶⁷ An effective antimalarial (a chloroquine-susceptible strain of *Plasmodium falciparum*), a hybrid concept of quinoline-linked pyridine (**91,92**) was developed.⁶⁸ The biological activity may be attributed to haem polymerization inhibition (HPI). It has been observed that ligands derived from acetyl pyridine possess anti-amoebic activity. However, it was observed that the anti-amoebic activity drastically increases when these ligands are coupled with ruthenium(II) to form a complex structure.⁶⁹ The anti-amoebic activity observed in complex (**93**) was much higher than that of the commercially available standard drug, metronidazole. The vanadium complex with 2-acetylpyridine exhibited higher amoebicidal activity (IC₅₀ value = 1.68–0.40) than the commercially available metronidazole (IC₅₀ value = 1.81), whereas only the ligand cannot act as the anti-amoebic agent. The pyridine derivative, which was synthesized by the reaction between pyridine-2-carboxaldehyde isonicotinoyl hydrazone (PCIH) with iron, produces a significantly stable complex. The synthesized compound acts as a chelating agent. Zeglis *et al.* reported a series of imidazo[1,2-*a*] pyridine derivatives synthesized to establish their cholesterol acyltransferase inhibition properties. Compounds (**94–98**) showed greater inhibitory properties compared to the rest of the synthesized compounds.^{70–72}

Some medicinally active pyridine-based analogues against various biological properties are summarized in the table given below (Table 1).

3. Pyridine-based scaffolds in marketed available drugs recently patented potent molecules and in bioactive natural products

Pyridine-based heterocycles are one of the most widely engaged pharmacophores in the field of drug development, mainly due to their intense pharmacological properties against various maladies, which resulted in the discovery of several therapeutic agents. Their incredible therapeutic applications have persuaded researchers to decorate a large number of biologically effective composites with pyridine to cure a variety of ailments. Several studies revealed that the






Fig. 14 Structure of pyridines Moiety for antimicrobial.




Fig. 15 Structure of 4-benzylsulfanylpyridine-2-carbohydrazides.






Fig. 16 Synthesis of 1H-pyrazolo [3,4-b]pyridine analogues.

pyridine moiety present in a drug molecule increases its biochemical potency and metabolic stability, enhances cellular permeability and fixes protein-binding issues. Hence, the pharmacokinetic and pharmacodynamic attributes of molecules are also enhanced by many folds. Amrinone and milrinone are the two marketed commercially available vasodilators containing pyridine in their pharmacophore. As per US-FDA, 95 approved pharmaceutical drugs originated from pyridine only.⁸¹ There is an overabundance of commercially

available drugs in the market, which contain pyridine rings, such as delavirdine for HIV/AIDS, isoniazid and ethionamide for tuberculosis, abiraterone acetate and crizotinib for cancer, ciclopirox for anthelmintic condition, tacrine for Alzheimer's, nifedipine for Raynaud's syndrome, piroxicam for arthritis, nilvadipine for hypertension, roflumilast for COPD,⁸² pyridostigmine for myasthenia gravis, enpiroline for malaria, nicotinamide for pellagra, nikethamide for respiratory stimulation, tropicamide for antimuscarinic effects, doxylamine




Fig. 17 Synthesis of thiazolo pyridine.






Fig. 18 Structures of pyridine compounds for various pharmacological evaluation.

Table 1 Medicinally potent pyridine-based compounds against various biological attributes.^{73–80}

Compound	Activity	Potency	Mechanism of Action
<p>1; R₁=R₂ 2; R₁=R₂ 3; R₁=R₂</p> <p>2,6-disubstituted pyridine hydrazones</p> <p>99</p>	Cytotoxic activity against HT-29 cell line	IC ₅₀ = 6.78, 8.88 and 8.26 μM respectively	Morphological changes of HT-29 and ISH cells and caspase-3 activation
<p>R=2,6-di-F</p> <p>Pyridine based Sulphonamides</p> <p>100</p>	Antidiabetic action	IC ₅₀ of alpha amylase inhibition is 54.18 ± 0.150 μg mL ⁻¹	Inhibition of α-amylase



Table 1 (Contd.)










Compound	Activity	Potency	Mechanism of Action
 <p>Schiff Bases of Inulin Bearing Pyridine ring</p> <p>101</p>	Antifungal activity	An inhibitory index of 77.0% against botrytis cinerea at 2.0 mg mL ⁻¹	Interaction with anionic components of the cell membranes, <i>i.e.</i> , glucan, mannan, proteins, and lipids, to destroy the cell membranes or to form an impervious layer preventing the transport of essential nutrients from entering the cell
 <p>1: R=4-OH-CH₄ 2: R=2-OH-3-OCH₃-CH₃</p> <p>pyrimidine-pyridine hybrids</p> <p>102</p>	Anti-inflammatory activity	COX-2 inhibitory activity in a range (IC ₅₀ = 0.25–0.89 mM)	Competitive selective COX-2 inhibitors
 <p>1: R=OCH₃, R₁=OCH₃, R₂-OCH₃, R₃=H</p> <p>Pyrimidine-Pyridine Hybrids</p> <p>103</p>	Ulcerogenic liability	High COX-2 selectivity with COX-2 S.I. = 17.08	Competitive selective COX-2 inhibitors
 <p>Pyridines and Pyridine Based Sulfa-Drugs</p> <p>104</p>	Antimicrobial activity	ZOI value 34 mm (more than the standard drug cefotaxime) against <i>E. coli</i>	Cell wall disruption
 <p>Pyridines and Pyridine Based Sulfa-Drugs</p> <p>105</p>	Antimicrobial activity	ZOI value 34 mm (more than the standard drug cefotaxime) against <i>Pseudomonas aeruginosa</i>	High cell permeability efficacy
 <p>Pyridinyl-thiadiazole Analogues</p> <p>106</p>	Antitubercular activity	Inhibitory activity of 0.06 μM against the MDR H37RV strain	Inhibition of RNA synthesis



Table 1 (Contd.)

Compound	Activity	Potency	Mechanism of Action
 Isoniazid Analogue 107	Antitubercular activity	Antimycobacterial activity of 1.2 $\mu\text{g mL}^{-1}$ against the MTB H37RV strain	Strong binding to the DNA-dependent RNA polymerase
 Isoniazid based Pyridine Analogues 108	Antimycobacterial activity	IC ₅₀ of 3.2 μM against the H37Rv strain	Inhibition of RNA synthesis
 Isoniazid based Pyridine Analogues 109	Antimycobacterial activity	IC ₅₀ of 1.5 μM against the H37Rv strain	Inhibition of RNA synthesis

for allergy conditions, omeprazole for ulcers, and enisamium iodide for influenza.⁸³

The drug resistance scenario and a better chemical nucleus to improvise the healthcare system to fight against disease conditions encouraged medicinal chemists to design a new molecule, which leads to a library of effective compounds. Recently, several patents for pyridine-based scaffolds to treat various maladies have been filed by many researchers, such as WO2020039097A1 (pyridine, dibenzylpyridine and dicarboxamide derivatives) for treating cancer as PI3K inhibitors (February 2020), US20200062754A1 (Fused amino pyridine) as hsp90 inhibitors(2020), WO2020039060A1 (4-substituted pyrrolo-pyridine) for treating cancer as erbb modulators (2020), WO2020033288A1 as PRMT5 inhibitors (2020), WO2020030925A1 for cancer (2020), US20200040002A1 (tricyclic fused thiophene derivatives) as JAK inhibitors (2020), US20200022983A1 for cancer as topoisomerase inhibitors (2020), CN110698491A (acetamide-pyridine analogues) for cancer (2020), WO2020014465A1 for polymorphic compounds (2020), US20200010458A1 (pyridine derivatives with tetrahydropyranylmethyl groups) abnormal cell (2020), US20200010420A1 (pyridyl inhibitors) for hedgehog signalling (2020), (US20200002310A1 9sulfonyl

amide derivatives) for the treatment of cancer and US20190367456A1 (biaryl compositions) for modulating a kinase cascade (2020).^{84,85} Many bioactive natural products also bear pyridine-based rings, including the coenzymes (*i.e.*, NAD and NADP), vitamins (*i.e.*, niacin and vitamin B6), antibiotics (*i.e.*, nikkomycin and collismycin), alkaloids (*i.e.*, trigonelline, oxirene, anabasine, huperzine A, paecilomide, and cystine)⁸⁶ and many other medicinally potent compounds. The figure shown below depicts some naturally occurring and commercially available pyridine-based drug molecules (Fig. 19).

4. Future direction

The simplest pyridine is a key unit in most of the drugs because of its characteristic chemical properties, such as basicity, solubility, hydrogen bond-forming ability, and able to act as the bioisosteres of amines, amides, heterocyclic rings containing nitrogen atoms. Due to these characteristic properties, pyridine units are incorporated in many drugs and pesticides. The replacement of a portion of drugs with a pyridine unit can improve its characteristic properties and this can be used in prodrug design strategies.






Fig. 19 Chemically available and naturally occurring pyridine-based drug molecules.

5. Conclusion

The biological activity of a drug depends largely on its physico-chemical properties, which can be improved by structural diversity. The scaffold pyridine has been largely used in making clinical candidates owing to its substituent bearing capacity at multiple centers, which has not only been useful in sharpening the potency but also helps in improving pharmacokinetics. From an overall perusal of the literature, it is observed that numerous pyridine analogues were useful against several microbes, but the fatal side effects and drug resistance are the two biggest challenges to the researchers. The overwhelming clinical responses of pyridine derivatives often encourage putting endeavors towards better research. In this review, several forms of pyridine were shown along with their biological properties such as antiviral, anticancer, antimicrobial, anti-diabetic, anti-tubercular, antileishmanial, anti-chagasic, antioxidant, anticoagulant and antithrombin. In some areas, synthetic strategies were also described. The in-detail explanation of different architectures of pyridine delivered a better understanding of both, the pattern and position of substituents on this skeleton and was deemed to be accountable for its effectiveness.

Conflicts of interest

The authors declare that they have no competing financial interests or personal relationships that could have appeared to influence the work reported in this study.

Acknowledgements

The authors are thankful to the Department of Pharmaceutical Technology, School of Medical Sciences, Adamas University, Vellore Institute of Technology Management, Vellore and Gupta College of Technological Sciences Management, Asansol, for providing resources to write this review.

References

- 1 X. Y. Lou and Y. W. Yang, *J. Am. Chem. Soc.*, 2021, **28**, 11976–11981.
- 2 G. D. Henry, *Tetrahedron*, 2004, **29**, 6043–6061.
- 3 E. D. Anderson and D. L. Boger, *J. Am. Chem. Soc.*, 2011, **133**, 12285–12292.
- 4 I. O. Zhuravel, S. M. Kovalenko, A. V Ivachtchenko, K. V Balakin and V. V Kazmirchuk, *Bioorg. Med. Chem. Lett.*, 2005, **15**, 5483–5487.
- 5 T. Suksrichavalit, S. Prachayasittikul, C. Nantasenamat, C. Isarankura-Na-Ayudhya and V. Prachayasittikul, *Eur. J. Med. Chem.*, 2009, **44**, 3259–3265.
- 6 S. L. Harer and M. S. Bhatia, *Chem. Sci. Trans.*, 2015, **4**, 1–16.
- 7 B. Leal, I. F. Afonso, C. R. Rodrigues, P. A. Abreu, R. Garrett, L. C. S. Pinheiro, A. R. Azevedo, J. C. Borges, P. F. Vegi and C. C. Santos, *Bioorg. Med. Chem.*, 2008, **16**, 8196–8204.
- 8 V. K. Zavyalova, A. A. Zubarev and A. M. Shestopalov, *Russ. Chem. Bull.*, 2009, **58**, 1939–1944.



- 9 P. C. Sharma and S. Jain, *Acta Pol. Pharm.*, 2008, **65**, 551–556.
- 10 A. M. R. Bernardino, L. C. da Silva Pinheiro, C. R. Rodrigues, N. I. Loureiro, H. C. Castro, A. Lanfredi-Rangel, J. Sabatini-Lopes, J. C. Borges, J. M. Carvalho and G. A. Romeiro, *Bioorg. Med. Chem.*, 2006, **14**, 5765–5770.
- 11 A. M. Attla, H. A. Mansour, A. A. Almevdi and M. M. Abbasi, *Nucleosides Nucleotides*, 1999, **18**, 2301–2306.
- 12 J.-M. Chezal, J. Paeshuyse, V. Gaumet, D. Canitrot, A. Maisonial, C. Lartigue, A. Gueiffier, E. Moreau, J.-C. Teulade and O. Chavignon, *Eur. J. Med. Chem.*, 2010, **45**, 2044–2047.
- 13 E. Abele, R. Abele and E. Lukevics, *Chem. Heterocycl. Compd.*, 2003, **39**, 825–865.
- 14 S. A. M. El-Hawash, A. E. Abdel Wahab and M. A. El-Demellawy, *Arch. Pharm.*, 2006, **339**, 14–23.
- 15 Z. Chen, P. Li, D. Hu, L. Dong, J. Pan, L. Luo, W. Zhang, W. Xue, L. Jin and B. Song, *Arabian J. Chem.*, 2019, **12**, 2685–2696.
- 16 A. Hartwich, N. Zdzienicka, D. Schols, G. Andrei, R. Snoeck and I. E. Głowacka, *Nucleosides, Nucleotides Nucleic Acids*, 2020, **39**, 542–591.
- 17 K. C. Nicolaou, R. Scarpelli, B. Bollbuck, B. Werschkun, M. M. A. Pereira, M. Wartmann, K. H. Altmann, D. Zaharevitz, R. Gussio and P. Giannakakou, *Chem. Biol.*, 2000, **7**, 593–599.
- 18 J.-K. Son, L.-X. Zhao, A. Basnet, P. Thapa, R. Karki, Y. Na, Y. Jahng, T. C. Jeong, B.-S. Jeong and C.-S. Lee, *Eur. J. Med. Chem.*, 2008, **43**, 675–682.
- 19 M. Hayakawa, H. Kaizawa, K. Kawaguchi, N. Ishikawa, T. Koizumi, T. Ohishi, M. Yamano, M. Okada, M. Ohta and S. Tsukamoto, *Bioorg. Med. Chem.*, 2007, **15**, 403–412.
- 20 R. Romagnoli, P. G. Baraldi, M. D. Carrion, O. Cruz-Lopez, C. L. Cara, M. Tolomeo, S. Grimaudo, A. Di Cristina, M. R. Pipitone and J. Balzarini, *Bioorg. Med. Chem. Lett.*, 2008, **18**, 5041–5045.
- 21 J.-P. Liou, K.-S. Hsu, C.-C. Kuo, C.-Y. Chang and J.-Y. Chang, *J. Pharmacol. Exp. Ther.*, 2007, **323**, 398–405.
- 22 P. Nagababu, D. A. Kumar, K. L. Reddy, K. A. Kumar, M. B. Mustafa, M. Shilpa and S. Satyanarayana, *Met.-Based Drugs*, 2008, **2008**, 1–8.
- 23 M. El-Naggar, H. Almahli, H. S. Ibrahim, W. M. Eldehna and H. A. Abdel-Aziz, *Molecules*, 2018, **23**, 1459.
- 24 P. V. S. Ramya, L. Guntuku, S. Angapelly, C. S. Digwal, U. J. Lakshmi, D. K. Sigalapalli, B. N. Babu, V. G. M. Naidu and A. Kamal, *Eur. J. Med. Chem.*, 2018, **143**, 216–231.
- 25 H. S. Khalaf, H. E. M. Tolan, M. N. El-Bayaa, M. A. A. Radwan, M. El-Manawaty and W. A. El-Sayed, *Russ. J. Gen. Chem.*, 2020, **90**, 1706–1715.
- 26 P. Thongaram, S. Borwornpinyo, P. Kanjanasirirat, K. Jearawuttanakul, M. Kongsema, N. Chuanopparat and P. Ngermmeesri, *Tetrahedron*, 2020, **76**, 131473.
- 27 E. Mansour, A. A. Abd-Rabou, I. F. Nassar and S. I. Elewa, *Polycyclic Aromat. Compd.*, 2021, 1–22.
- 28 C. S. Rani, A. G. Reddy, E. Susithra, K.-K. Mak, M. R. Pichika, S. Reddymasu and M. V. B. Rao, *Med. Chem. Res.*, 2021, **30**, 74–83.
- 29 V. Barresi, D. F. Condorelli, C. G. Fortuna, G. Musumarra and S. Scirè, *Bioorg. Med. Chem.*, 2002, **10**, 2899–2904.
- 30 M. B. Gurdere, B. Yilmaz and Y. Budak, *Synth. Commun.*, 2014, **44**, 981–986.
- 31 M. T. Cocco, C. Congiu, V. Lilliu and V. Onnis, *Bioorg. Med. Chem.*, 2007, **15**, 1859–1867.
- 32 V. Onnis, M. T. Cocco, V. Lilliu and C. Congiu, *Bioorg. Med. Chem.*, 2008, **16**, 2367–2378.
- 33 B. L. Furman, *Curr. Protoc.*, 2021, **1**, e78.
- 34 R. H. Bahekar, M. R. Jain, P. A. Jadav, V. M. Prajapati, D. N. Patel, A. A. Gupta, A. Sharma, R. Tom, D. Bandyopadhyaya and H. Modi, *Bioorg. Med. Chem.*, 2007, **15**, 6782–6795.
- 35 B. Y. Kim, J. B. Ahn, H. W. Lee, S. K. Kang, J. H. Lee, J. S. Shin, S. K. Ahn, C. Il Hong and S. S. Yoon, *Eur. J. Med. Chem.*, 2004, **39**, 433–447.
- 36 L. Suresh, P. S. V. Kumar, P. Onkar, L. Srinivas, Y. Pydisetty and G. V. P. Chandramouli, *Res. Chem. Intermed.*, 2017, **43**, 5433–5451.
- 37 M. Adib, F. Peytam, M. Rahmanian-Jazi, M. Mohammadi-Khanaposhtani, S. Mahernia, H. R. Bijanzadeh, M. Jahani, S. Imanparast, M. A. Faramarzi and M. Mahdavi, *New J. Chem.*, 2018, **42**, 17268–17278.
- 38 F. Ma, J. Liu, T. Zhou, M. Lei, J. Chen, X. Wang, Y. Zhang, X. Shen and L. Hu, *Eur. J. Med. Chem.*, 2018, **152**, 307–317.
- 39 A. Ozdemir, G. Turan-Zitouni, Z. A. Kaplancıklı, G. Işcan, S. Khan and F. Demirci, *Eur. J. Med. Chem.*, 2010, **45**, 2080–2084.
- 40 E. R. Shakurova, D. A. Pozdnyakova, E. V. Tretyakova and L. V. Parfenova, *Lett. Drug Des. Discovery*, 2020, **17**, 79–84.
- 41 A. Altundas, S. Ayvaz and E. Logoglu, *Med. Chem. Res.*, 2011, **20**, 1–8.
- 42 S. M. Sondhi, M. Dinodia and A. Kumar, *Bioorg. Med. Chem.*, 2006, **14**, 4657–4663.
- 43 B. N. Acharya, D. Thavaselvam and M. P. Kaushik, *Med. Chem. Res.*, 2008, **17**, 487–494.
- 44 M. Shekarchi, M. Pirali-Hamedani, L. Navidpour, N. Adib and A. Shafiee, *J. Iran. Chem. Soc.*, 2008, **5**, 150–158.
- 45 E. Kita and R. Lisiak, *Transition Met. Chem.*, 2010, **35**, 441–450.
- 46 N. Bharti, M. R. Maurya, F. Naqvi and A. Azam, *Bioorg. Med. Chem. Lett.*, 2000, **10**, 2243–2245.
- 47 M. R. Maurya, S. Agarwal, M. Abid, A. Azam, C. Bader, M. Ebel and D. Rehder, *Dalton Trans.*, 2006, 937–947.
- 48 M. V Pavlova, A. I. Mikhalev, M. E. Kon'shin, M. Y. Vasil'eva, L. G. Mardanova, T. F. Odegova and M. I. Vakhryn, *Pharm. Chem. J.*, 2001, **35**, 664–666.
- 49 M. G. Mamolo, D. Zampieri, V. Falagiani, L. Vio and E. Banfi, *Farm.*, 2001, **56**, 593–599.
- 50 M. G. Mamolo, V. Falagiani, D. Zampieri, L. Vio and E. Banfi, *Farm.*, 2001, **56**, 587–592.
- 51 G. Navarrete-Vazquez, G. Mari, Z. V. Duarte-Fajardo, J. Vargas-Villarreal, S. Estrada-Soto, F. González-Salazar, E. Hernández-Núñez and S. Said-Fernández, *Bioorg. Med. Chem.*, 2007, **15**, 5502–5508.
- 52 F. E. Goda, A.-M. Alaa and O. A. Attef, *Bioorg. Med. Chem.*, 2004, **12**, 1845–1852.



- 53 I. O. Zhuravel, S. M. Kovalenko, A. V. Ivachtchenko, K. V. Balakin and V. V. Kazmirchuk, *Bioorg. Med. Chem. Lett.*, 2005, **15**, 5483–5487.
- 54 S. L. Gaonkar, K. M. L. Rai and B. Prabhushwamy, *Eur. J. Med. Chem.*, 2006, **41**, 841–846.
- 55 M. S. Yar, M. A. ALIa, D. Sriram and P. Yogeewari, *Acta Pol. Pharm.*, 2015, **63**, 491–496.
- 56 S. L. Gaonkar, K. M. L. Rai and B. Prabhushwamy, *Med. Chem. Res.*, 2007, **15**, 407–417.
- 57 P. Mishra, T. Lukose and S. K. Kashaw, *Indian J. Pharm. Sci.*, 2007, **69**, 665.
- 58 S. Mehta, N. Swarnkar, R. Vyas, J. Vardia, P. B. Punjabi and S. C. Ameta, *Phosphorus, Sulfur Silicon Relat. Elem.*, 2007, **183**, 105–114.
- 59 V. Aanandhi, S. George and V. Vaidhyalingam, *Arkivoc*, 2008, **11**, 187–194.
- 60 A. Riahi, M. Wurster, M. Lalk, U. Lindequist and P. Langer, *Bioorg. Med. Chem.*, 2009, **17**, 4323–4326.
- 61 J. J. Vora, S. B. Vasava, K. C. Parmar, S. K. Chauhan and S. S. Sharma, *E-J. Chem.*, 2009, **6**, 1205–1210.
- 62 D. Sriram, P. Yogeewari and K. Madhu, *Bioorg. Med. Chem. Lett.*, 2006, **16**, 876–878.
- 63 P. Herzigova, V. Klimesova, K. Palat, J. Kaustova, H. Dahse and U. Mollmann, *Arch. Pharm.*, 2009, **342**, 394–404.
- 64 L. R. S. Dias, M. B. Santos, S. de Albuquerque, H. C. Castro, A. M. T. de Souza, A. C. C. Freitas, M. A. V DiVaio, L. M. Cabral and C. R. Rodrigues, *Bioorg. Med. Chem.*, 2007, **15**, 211–219.
- 65 F. Shi, C. Li, M. Xia, K. Miao, Y. Zhao, S. Tu, W. Zheng, G. Zhang and N. Ma, *Bioorg. Med. Chem. Lett.*, 2009, **19**, 5565–5568.
- 66 A. Worachartcheewan, S. Prachayasittikul, R. Pingaew, C. Nantasenamat, T. Tantimongcolwat, S. Ruchirawat and V. Prachayasittikul, *Med. Chem. Res.*, 2012, **21**, 3514–3522.
- 67 C. M. Timperley, M. Bird, S. C. Heard, S. Notman, R. W. Read, J. E. H. Tattersall and S. R. Turner, *J. Fluorine Chem.*, 2005, **126**, 1160–1165.
- 68 N. Bharti, M. R. Maurya, F. Naqvi and A. Azam, *Bioorg. Med. Chem. Lett.*, 2000, **10**, 2243–2245.
- 69 J. T. E. Lim, G. A. Piazza, E. K. H. Han, T. M. Delohery, H. Li, T. S. Finn, R. Buttyan, H. Yamamoto, G. J. Sperl and K. Brendel, *Biochem. Pharmacol.*, 1999, **58**, 1097–1107.
- 70 B. M. Zeglis, V. Divilov and J. S. Lewis, *J. Med. Chem.*, 2011, **54**, 2391–2398.
- 71 T. B. Chaston and D. R. Richardson, *JBIC, J. Biol. Inorg. Chem.*, 2003, **8**, 427–438.
- 72 A. Deep, R. K. Bhatia, R. Kaur, S. Kumar, U. J. Kumar, H. Singh, S. Batra, D. Kaushik and P. D. Kishore, *Curr. Top. Med. Chem.*, 2017, **17**, 238–250.
- 73 S. Şenkardes, A. Ture, S. Ekrek, A. T. Durak, M. Abbak, O. Çevik, B. Kaskatepe, I. Kuçukguzel and S. G. Kuçukguzel, *J. Mol. Struct.*, 2021, **1223**, 128962.
- 74 G. Sadawarte, S. Jagatap, M. Patil, V. Jagrut and J. D. Rajput, *Eur. J. Chem.*, 2021, **12**, 279–283.
- 75 L. Wei, W. Tan, J. Zhang, Y. Mi, F. Dong, Q. Li and Z. Guo, *Polymers*, 2019, **11**, 371.
- 76 M. A. Abdelgawad, R. B. Bakr and A. A. Azouz, *Bioorg. Chem.*, 2018, **77**, 339–348.
- 77 H. A. El-Sayed, A. H. Moustafa, A. E. El-Torky and A. El-Salam, *Russ. J. Gen. Chem.*, 2017, **87**, 2401–2408.
- 78 H. M. Patel, M. N. Noolvi, N. S. Sethi, A. K. Gadad and S. S. Cameotra, *Arabian J. Chem.*, 2017, **10**, S996–S1002.
- 79 K. S. Chaudhari, H. M. Patel and S. J. Surana, *Indian J. Tuberc.*, 2017, **64**, 119–128.
- 80 H. Patel, K. Chaudhari, P. Jain and S. Surana, *Bioorg. Chem.*, 2020, **102**, 104099.
- 81 S. R. Alizadeh and M. A. Ebrahimzadeh, *Mini-Rev. Med. Chem.*, 2021, **21**, 2584–2611.
- 82 R. Sahu, R. Mishra R, R. Kumar, A. Mazumder and A. Kumar, *Indian J. Pharm. Sci.*, 2021, **83**, 162–185.
- 83 H. Dai, M. Huang, J. Qian, *et al.*, *Eur. J. Med. Chem.*, 2019, **166**, 470–479.
- 84 Z. Cournia, A. Efstratiadis, A. Kapella, E. Couladouros and S. Christoforidis, WO2020039097A1, 2020.
- 85 A. Z. Abdelazem, M. M. Al-Sanea, M. H. Park and S. H. Lee, *Bioorg. Med. Chem. Lett.*, 2016, **26**, 1301–1304.
- 86 Y. Ling, Z. Y. Hao, D. Liang, C. L. Zhang, Y. F. Liu and Y. Wang, *Drug Des., Dev. Ther.*, 2021, **15**, 4289.

